In the real world, treating relapsed/refractory large B-cell lymphoma with epcoritamab and glofitamab leads to poorer ...
Jazz Pharmaceuticals (NASDAQ:JAZZ) and Zymeworks (NASDAQ:ZYME) announced Thursday the FDA approval of their jointly developed bispecific antibody Ziihera as a late-line treatment for certain adults ...
In a report released on November 21, David Martin PhD from Bloom Burton maintained a Buy rating on Zymeworks (ZYME – Research Report), with a ...
Jazz Pharmaceuticals has claimed FDA approval for its HER2-directed bispecific antibody Ziihera as a treatment for biliary ...
Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company's proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, ...
Zymeworks, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific ...
And, pending approval, Zymeworks is eligible to receive tiered royalties between 10% and 20% on Jazz’s net sales. Zanidatamab is an HER2-targeted bispecific antibody with multiple novel ...
The bispecific antibody is currently under FDA priority review for biliary tract cancer, with a target action date of Nov. 29 ...
Zymeworks, Inc. is a biopharmaceutical company ... Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor ...
Ziihera is one of several variations of the bispecific antibody Zanidatamab that Zymeworks developed for treating various types of cancer, and one of three in the advanced “pivotal” trial phase.